Jazz Pharmaceuticals up 14% on Upbeat Earnings

by Eddie Staley, Benzinga Editor
July 29, 2011 11:06 AM | 14 seconds read |
Jazz Pharmaceuticals JAZZ is up 14% on the upbeat earnings reported yesterday after the close. The company reported Q2 EPS $0.82 vs $0.77 Est; Revenues $64.6M vs $61.86M Est. Jazz Pharmaceuticals is currently trading at $40.12, a gain of $4.85 or 13.75%.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Intraday UpdateMoversHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!